AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease
STOCKHOLM, SWEDEN / ACCESS Newswire / February 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN ...
AlzeCure Pharma: AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease
STOCKHOLM, SWEDEN / ACCESS Newswire / February 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for di ...
First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive Heart Failure
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...
GlobalData on MSN1d
AlzeCure Pharma secures €2.5m grant for Phase IIa trial of Alzheimer’s treatment
The trial will explore the effects of higher doses of ACD856, building on the drug’s established safety profile.
Asklepios BioPharmaceutical, Inc. (AskBio): First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive Heart Failure
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) ...
The American Journal of Managed Care3d
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing ...
Medscape10h
European Commission Approves Nemolizumab for Atopic Dermatitis and Prurigo Nodularis
The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markersFull analysis of Phase 2 ...
Business Wire10h
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...
Advanced Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis ...